

BIO REFERENCE LABORATORIES INC  
Form 10-Q  
June 09, 2015  
[Table of Contents](#)

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934.**

For the quarterly period ended April 30, 2015

Or

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number 000-15266

**BIO-REFERENCE LABORATORIES, INC.**

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

(Exact name of registrant as specified in its charter)

**NEW JERSEY**

(State or other jurisdiction of incorporation or organization)

**22-2405059**

(IRS Employer Identification No.)

**481 Edward H. Ross Drive, Elmwood Park, NJ**

(Address of principal executive offices)

**07407**

(Zip Code)

**(201) 791-2600**

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated Filer

Non-accelerated Filer

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

**APPLICABLE ONLY TO CORPORATE ISSUERS:**

Indicate the number of shares outstanding of the issuer's common stock, as of the latest practicable date: 27,802,976 shares of Common Stock (\$.01 par value) at June 3, 2015.



Table of Contents

**BIO-REFERENCE LABORATORIES, INC.**

**FORM 10-Q**

**April 30, 2015**

**I N D E X**

	<b>Page</b>
<b><u>PART I. FINANCIAL INFORMATION</u></b>	
Item 1. Financial Statements	
<u>Consolidated Balance Sheets as of April 30, 2015 (unaudited) and October 31, 2014.</u>	1
<u>Consolidated Statements of Operations (unaudited) for the three months and six-months ended April 30, 2015 and April 30, 2014</u>	3
<u>Consolidated Statements of Cash Flows (unaudited) for the six-months ended April 30, 2015 and April 30, 2014</u>	4
<u>Notes to consolidated financial statements (unaudited)</u>	6
<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	10
<u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u>	16
<u>Item 4. Controls and Procedures</u>	16
<b><u>PART II. OTHER INFORMATION</u></b>	<b>17</b>
<u>Item 1. Legal Proceedings</u>	17
<u>Item 5. Other Information</u>	17
<u>Item 6. Exhibits</u>	17
<u>Signatures</u>	18

---

Table of Contents**PART I FINANCIAL INFORMATION****BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES****CONSOLIDATED BALANCE SHEETS**

[Dollars In Thousands Except Share and Per Share Data]

**ASSETS**

	April 30, 2015 (Unaudited)	October 31, 2014
<b><u>CURRENT ASSETS:</u></b>		
Cash and Cash Equivalents	\$ 25,146	\$ 17,507
Accounts Receivable - Net	285,361	263,346
Inventory	20,783	20,791
Other Current Assets	9,224	10,165
Deferred Tax Assets	39,456	40,040
<b><u>TOTAL CURRENT ASSETS</u></b>	<b>379,970</b>	<b>351,849</b>
<b><u>PROPERTY AND EQUIPMENT - AT COST</u></b>	<b>172,893</b>	<b>156,342</b>
<b><u>LESS: Accumulated Depreciation</u></b>	<b>(101,250)</b>	<b>(89,954)</b>
<b><u>PROPERTY AND EQUIPMENT - NET</u></b>	<b>71,643</b>	<b>66,388</b>
<b><u>OTHER ASSETS:</u></b>		
Investments in Unconsolidated Affiliate	5,290	5,153
Deposits	1,127	1,056
Goodwill - Net	35,185	35,185
Intangible Assets - Net	13,450	14,403
Other Assets	1,615	1,415
Deferred Tax Asset	4,438	3,414
<b><u>TOTAL OTHER ASSETS</u></b>	<b>61,105</b>	<b>60,626</b>
<b><u>TOTAL ASSETS</u></b>	<b>\$ 512,718</b>	<b>\$ 478,863</b>

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements.

Table of Contents**BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES****CONSOLIDATED BALANCE SHEETS**

[Dollars In Thousands Except Share and Per Share Data]

**LIABILITIES AND SHAREHOLDERS EQUITY**

	April 30, 2015 (Unaudited)	October 31, 2014
<b><u>CURRENT LIABILITIES:</u></b>		
Accounts Payable	\$ 66,073	\$ 71,166
Accrued Salaries and Commissions Payable	26,950	15,822
Accrued Taxes and Expenses	11,493	15,620
Other Short Term Acquisition Payable	1,695	1,924
Revolving Note Payable - Bank	49,315	33,380
Current Maturities of Long-Term Debt	541	524
Capital Lease Obligations - Short-Term Portion	6,259	6,128
<b><u>TOTAL CURRENT LIABILITIES</u></b>	<b>162,326</b>	<b>144,564</b>
<b><u>LONG-TERM LIABILITIES</u></b>		
Capital Lease Obligations - Long-Term Portion	10,863	12,252
Long - Term Debt Net of Current Portion	2,871	3,145
<b><u>TOTAL LONG-TERM LIABILITIES</u></b>	<b>13,734</b>	<b>15,397</b>
<b><u>SHAREHOLDERS EQUITY</u></b>		
Preferred Stock \$.10 Par Value; Authorized 1,666,667 shares, including 3,000 shares of Series A Junior Preferred Stock None Issued	0	0
Common Stock, \$.01 Par Value; Authorized 35,000,000 shares: Issued and Outstanding 27,798,976 and 27,272,644 at April 30, 2015 and at October 31, 2014, respectively	278	277
Additional Paid-In Capital	40,640	39,979
Retained Earnings	295,740	278,646
<b><u>TOTAL SHAREHOLDERS EQUITY</u></b>	<b>336,658</b>	<b>318,902</b>
<b><u>TOTAL LIABILITIES AND SHAREHOLDERS EQUITY</u></b>	<b>\$ 512,718</b>	<b>\$ 478,863</b>

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements.

Table of Contents**BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES****CONSOLIDATED STATEMENTS OF OPERATIONS**

[Dollars In Thousands Except Share and Per Share Data]

**[UNAUDITED]**

	Three months ended April 30,		Six months ended April 30,	
	2015	2014	2015	2014
<b><u>NET REVENUES:</u></b>	\$ 223,986	\$ 201,366	\$ 432,820	\$ 382,635
<b><u>COST OF SERVICES:</u></b>				
Depreciation and Amortization	5,091	4,659	10,057	9,234
Employee Related Expenses	56,491	51,566	110,176	100,676
Reagents and Laboratory Supplies	42,977	38,352	83,559	75,583
Other Cost of Services	20,444	18,240	40,290	36,439
<b><u>TOTAL COST OF SERVICES</u></b>	<b>125,003</b>	<b>112,817</b>	<b>244,082</b>	<b>221,932</b>
<b><u>GROSS PROFIT ON REVENUES</u></b>	<b>98,983</b>	<b>88,549</b>	<b>188,738</b>	<b>160,703</b>
<b><u>GENERAL AND ADMINISTRATIVE EXPENSES:</u></b>				
Depreciation and Amortization	1,606	1,586	3,174	2,700
General and Administrative Expenses	58,797	50,992	117,056	100,578
Bad Debt Expense	19,654	17,092	37,654	32,665
<b><u>TOTAL GENERAL AND ADMINISTRATIVE EXPENSES</u></b>	<b>80,057</b>	<b>69,670</b>	<b>157,884</b>	<b>135,943</b>
<b><u>INCOME FROM OPERATIONS</u></b>	<b>18,926</b>	<b>18,879</b>	<b>30,854</b>	<b>24,760</b>
<b><u>OTHER (INCOME) EXPENSE:</u></b>				
Interest Expense	666	597	1,226	1,206
Interest Income	(23)	(12)	(45)	(26)
Other (Income) Expense	2	56	(112)	86
<b><u>TOTAL OTHER (INCOME) EXPENSES - NET</u></b>	<b>645</b>	<b>641</b>	<b>1,069</b>	<b>1,266</b>
<b><u>INCOME BEFORE INCOME TAXES</u></b>	<b>18,281</b>	<b>18,238</b>	<b>29,785</b>	<b>23,494</b>
Provision for Income Taxes	7,820	7,965	12,691	10,267
<b><u>NET INCOME</u></b>	<b>\$ 10,461</b>	<b>\$ 10,273</b>	<b>\$ 17,094</b>	<b>\$ 13,227</b>
<b><u>NET INCOME PER COMMON SHARE - BASIC:</u></b>	<b>\$ 0.38</b>	<b>\$ 0.37</b>	<b>\$ 0.62</b>	<b>\$ 0.48</b>
<b><u>WEIGHTED AVERAGE NUMBER OF SHARES - BASIC:</u></b>	<b>27,786,309</b>	<b>27,716,644</b>	<b>27,781,143</b>	<b>27,712,525</b>
<b><u>NET INCOME PER COMMON SHARE - DILUTED:</u></b>	<b>\$ 0.38</b>	<b>\$ 0.37</b>	<b>\$ 0.61</b>	<b>\$ 0.47</b>
<b><u>WEIGHTED AVERAGE NUMBER OF SHARES - DILUTED:</u></b>	<b>27,881,908</b>	<b>27,857,467</b>	<b>27,874,074</b>	<b>27,855,141</b>

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements.



Table of Contents**BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES****CONSOLIDATED STATEMENTS OF CASH FLOWS**

[Dollars In Thousands Except Share and Per Share Data]

**[UNAUDITED]**

	Six months ended April, 30	
	2015	2014
<b><u>OPERATING ACTIVITIES:</u></b>		
Net Income	\$ 17,094	\$ 13,227
Adjustments to Reconcile Net Income to Cash Provided by (Used for) Operating Activities:		
Depreciation and Amortization	13,231	11,934
Deferred Income Tax (Benefit) Expense	(440)	5,976
Stock Based Compensation	40	290
(Gain) Loss on Disposal of Fixed Assets	173	109
Undistributed Equity Method (Income) Loss	(112)	86
Change in Assets and Liabilities, (Increase) Decrease in:		
Accounts Receivable	(20,244)	(13,227)
Provision for Doubtful Accounts	(1,771)	(14,480)
Inventory	8	(855)
Other Current Assets	941	87
Other Assets	(200)	(200)
Deposits	(71)	(38)
Increase (Decrease) in:		
Accounts Payable and Accrued Liabilities	1,908	(3,097)
<b><u>NET CASH - OPERATING ACTIVITIES</u></b>	<b>10,557</b>	<b>(188)</b>
<b><u>INVESTING ACTIVITIES:</u></b>		
Acquisition of Equipment and Leasehold Improvements	(15,739)	(7,048)
Business Acquisitions and Related Costs	(254)	(258)
<b><u>NET CASH - INVESTING ACTIVITIES</u></b>	<b>(15,993)</b>	<b>(7,306)</b>
<b><u>FINANCING ACTIVITIES:</u></b>		
Payments of Long-Term Debt	(257)	(243)
Payments of Capital Lease Obligations	(3,225)	(2,933)
Increase (Decrease) in Revolving Line of Credit	15,935	17,021
Proceeds from Exercise of Options	622	177
<b><u>NET CASH - FINANCING ACTIVITIES</u></b>	<b>13,075</b>	<b>14,022</b>
<b><u>NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</u></b>	<b>7,639</b>	<b>6,528</b>
<b><u>CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIODS</u></b>	<b>17,507</b>	<b>17,952</b>
<b><u>CASH AND CASH EQUIVALENTS AT END OF PERIODS</u></b>	<b>\$ 25,146</b>	<b>\$ 24,480</b>

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:

Cash paid during the period for:

Interest	\$	1,189	\$	1,166
Income Taxes	\$	16,538	\$	9,867

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements.

Table of Contents

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

[Dollars In Thousands]

[UNAUDITED]

During the six-month periods ended April 30, 2015 and April 30, 2014, the Company entered into capital leases totaling \$1,967 and \$5,905, respectively.

During the six-month periods ended April 30, 2015 and April 30, 2014, the Company wrote-off approximately \$1,155 and \$920 of property and equipment, most of which were fully depreciated.

Table of Contents

**BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**[Dollars In Thousands Except Share and Per Share Data, Or Unless Otherwise Noted]**

**(UNAUDITED)**

**[1] Basis of Presentation**

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the instructions to Form 10-Q and, therefore, do not include all information and footnotes necessary for complete audited financial statements. However, in the opinion of the management of the Company, all adjustments necessary for a fair presentation of the financial position and operating results have been included in these statements. Interim results are not necessarily indicative of results for a full year. Reference is made to the October 31, 2014 audited consolidated financial statements of Bio-Reference Laboratories, Inc. ( BRLI or the Company ) contained in its Annual Report on Form 10-K for the year ended October 31, 2014.

The consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes for the year ended October 31, 2014 as filed with the Securities and Exchange Commission in the Company's Annual Report on Form 10-K. Significant accounting policies followed by the Company are set forth in Note 2 to the Company's 2014 Annual Report on Form 10-K.

**[2] Fair Value Measurements**

As of April 30, 2015, the Company's financial instruments primarily consist of cash, short-term trade receivables and payables for which their carrying amounts approximate fair values, and long term debt, for which based on the borrowing rates currently available to the Company for bank loans with similar terms and average maturities, its carrying amount approximates its fair value.

**[3] New Accounting Pronouncements**

Removed and Reserved.

**[4] Revenue Recognition and Contractual Adjustments**

## Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

Service revenues are principally generated from laboratory testing services including chemical diagnostic tests such as blood analysis, urine analysis and genetic testing among others. Service revenues are recognized at the time the testing services are performed and are reported at their estimated net realizable amounts.

Service revenues before provision for bad debts are determined utilizing gross service revenues net of contractual adjustments and discounts. Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or a commercial insurance provider to pay all or a portion of their healthcare expenses; the majority of services provided by BRLI are to patients covered under a third party payor contract. In certain cases, the individual has no insurance or does not provide insurance information and in other cases tests are performed under contract to a professional organization (such as physicians, hospitals, and clinics) which reimburse BRLI directly; in the remainder of the cases, BRLI is provided the third party billing information and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI. Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and providing coverage (reimbursement) for specific tests. Estimated revenues are established based on a series of highly complex procedures and judgments that require industry specific healthcare experience and an understanding of payor methods and trends. We review our calculations on a monthly basis in order to make certain that we are properly allowing for the uncollectable portion of our gross billings due to the contractual adjustments and discounts and that our estimates remain sensitive to variances and changes within our payor groups. The contractual allowance calculation is made on the basis of historical allowance rates for the various specific payor groups on a monthly basis with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions and shifts in the testing being performed. This calculation is routinely analyzed by BRLI on the basis of actual allowances issued by payors and the actual payments made to determine what adjustments, if any, are needed. The table below shows the adjustments made to gross service revenues to arrive at net revenues, the amount reported on our statement of operations.

Table of Contents

	(\$)			
	Three Months Ended April 30, [Unaudited]		Six Months Ended April 30, [Unaudited]	
	2015	2014	2015	2014
Gross Service Revenues	1,175,282	1,017,621	2,240,575	1,927,499
Contractual Adjustments and Discounts:				
Medicare/Medicaid Portion	101,262	94,520	195,325	183,439
All Other Third Party Payors*	838,004	706,234	1,587,205	1,330,379
Total Contractual Adjustments and Discounts	939,266	800,754	1,782,530	1,513,818
Service Revenues Net of Contractual Adjustments and Discounts	236,016	216,867	458,045	413,681
Patient Service Revenue Provision for Bad Debts**	12,030	15,501	25,225	31,046
Net Revenues	223,986	201,366	432,820	382,635

\* All Other Third Party and Direct Payors consists of almost eight hundred distinct payors, including commercial health insurers and administrators as well as professionally billed accounts such as physicians, hospitals, clinics and other direct billed accounts.

\*\* Represents the amount of Bad Debt Expense that is required to be presented as a deduction from patient service revenue (net of contractual allowances and discounts) pursuant to ASU No. 2011-7.

When new business is received by BRLI, service revenues net of contractual adjustments and discounts are calculated by reducing gross service revenues by the estimated contractual allowance. The Patient Service Revenue Provision for Bad Debts represents the amount of bad debt expense expected to occur on patient service revenue based upon our experience. The remaining bad debt expense is presented as part of operating expenses. The bad debt expense presented as part of operating expense represents the bad debt expense related to receivables from service revenues determined after taking into account our ability to collect on such revenue.

BRLI recognized the amounts in subsequent periods for actual allowances/discounts to gross service revenue; bad debt may have been adjusted over the same periods of time to maintain an accurate balance between net revenues and actual revenues. Management has reviewed the allowances/discounts recognized in subsequent periods and believes the amounts to be immaterial. A number of proposals for legislation or regulation continue to be under discussion which could have the effect of substantially reducing Medicare reimbursements for clinical laboratories or introducing cost sharing to beneficiaries. One such legislation is Protecting Access to Medicare Act of 2014 (Public Law 113-93) (PAMA) was signed into law on April 1, 2014. The legislation directed CMS to conduct a market survey and to determine whether Medicare is reimbursing at a commercially reasonable rates. To date, CMS has fallen behind the schedule legislated in PAMA. As the result, the current reimbursement rates remain unchanged, subject to typical annual reviews, until 2017.

**[5] Accounts Receivable Allowances**

## Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

It is typically the responsibility of the patient to pay for laboratory service bills. Most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or commercial insurance to pay all or a portion of their healthcare expenses; this represents the major portion of payment for all services provided by BRLI. In certain cases, the individual has no insurance or does not provide insurance information; in the remainder of the cases, BRLI is provided the third party billing information, usually by the referring physician, and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI. Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and coverage of specific tests. BRLI routinely reviews the reimbursement policies and subsequent payments and collection rates from these different types of payors. Contractual adjustments and discounts are recorded as reductions to gross service revenues and are collectively referred to as the contractual allowance. BRLI has not been required to record an adjustment in a subsequent period related to revenue recorded in a prior period which was material in nature. Aging of accounts receivable is monitored by billing personnel and follow-up activities including collection efforts are conducted as necessary. BRLI writes off receivables against the allowance for doubtful accounts when they are deemed uncollectible. For client billing, accounts are written off when all reasonable collection efforts prove to be unsuccessful. Patient accounts, where the patient is directly responsible for all or a remainder portion of the account after partial payment or denial by a third party payor, are written off after the normal dunning cycle has occurred, although these may be subsequently transferred to a third party collection agency after being written off. Third party payor accounts are written off when they exceed the payer's timely filing limits. Accounts Receivable on the balance sheet is net of the following amounts for contractual credits and doubtful accounts:

Table of Contents

	[Unaudited] April 30, 2015	(\$) October 31, 2014
Contractual Credits/Discounts	582,180	513,466
Doubtful Accounts	81,505	83,276
Total Allowance	663,685	596,742

**[6] Intangible Assets**

The following disclosures present certain information on the Company's intangible assets as of April 30, 2015 (Unaudited) and October 31, 2014. All intangible assets are being amortized over their estimated useful lives, as indicated below, with no estimated residual value.

April 30, 2015

Intangible Asset	Weighted-Average Amortization Period Years	Cost (\$)	Accumulated Amortization (\$)	Net of Accumulated Amortization (\$)
Customer Lists	20	8,738	3,469	5,269
Covenants				
Not-to-Compete	5	11,131	6,325	4,806
Patents and Licenses	17	5,297	1,922	3,375
Totals		25,166	11,716	13,450

October 31, 2014

Intangible Asset	Weighted-Average Amortization Period Years	Cost (\$)	Accumulated Amortization (\$)	Net of Accumulated Amortization (\$)
Customer Lists	20	\$ 8,738	\$ 3,275	\$ 5,463
Covenants				
Not-to-Compete	3	11,131	5,738	5,393
Patents and Licenses	17	5,297	1,750	3,547
Totals		\$ 25,166	\$ 10,763	\$ 14,403

The aggregate intangible amortization expense for the three months ended April 30, 2015 and 2014 was \$474 and \$730, respectively. The aggregate intangible amortization expense for the six months ended April 30, 2015 and 2014 was \$952 and \$959, respectively. The estimated intangible asset amortization expense for the remainder of fiscal year ending October 31, 2015 and for the four subsequent years is as follows:



October 31,	(\$)
2015	900
2016	1,540
2017	1,063
2018	946
2019	904
Thereafter	8,097
<b>Total</b>	13,450

**[7] Revolving Note Payable - Bank**

On February 3, 2014, the Company entered into an amended revolving note payable loan agreement with PNC Bank, N.A. ( PNC Bank Credit Line ). This amendment increased the maximum credit line to \$70,000. The maximum amount of the credit line available to the Company pursuant to the loan agreement is the lesser of (i) \$70,000 or (ii) 50% of the Company's

Table of Contents

qualified accounts receivable, as defined in the agreement. The amendment to the Loan and Security Agreement provides for an interest rate on advances to be subject, at the election of the Company, to either the bank's base rate or the Eurodollar rate of interest plus, in certain instances, an additional interest percentage. The additional interest percentage charge on bank's base rate borrowings and on Eurodollar rate borrowings ranges from 1% to 4% and is determined based upon certain financial ratios achieved by the Company. At April 30, 2015, the Company elected to have all of the total advances outstanding to be subject to the bank's base rate of interest of 3.50%. The credit line is collateralized by substantially all of the Company's assets. The line of credit is available through October 2016 and may be extended for annual periods by mutual consent, thereafter. The terms of this agreement contain, among other provisions, requirements for maintaining defined levels of capital expenditures and fixed charge coverage, and the prohibition of the payment of cash dividends by the Company. As of April 30, 2015, the Company utilized \$49,315 of the available credit under this revolving note payable loan agreement.

On May 14, 2015 a date subsequent to the period covered in these financial statements the Company further amended its PNC Bank Credit Line to increase the maximum that can be borrowed under the credit line to \$120,000 as well as extended the credit line through October 2020. This amendment is effective as of May 5, 2015. The other terms of the amendment remained substantially unchanged.

**[8] Long-Term Debt - Bank**

In December 2010, the Company issued a seven-year term note for \$5,408 at the rate of interest of 6.12% per annum for the financing of new equipment. The note is payable in 84 equal monthly installments commencing on January 29, 2011 of \$61 including principal and interest followed by a balloon payment of the principal and interest outstanding on the loan repayment date of December 29, 2017. The balance on this note as of April 30, 2015 is approximately \$3,412.

**[9] Provision for Income Taxes**

The provision for income taxes for the three-months ended April 30, 2015 consists of a current tax provision of \$9,400 and a deferred tax benefit of \$1,580.

The provision for income taxes for the six-months ended April 30, 2015 consists of a current tax provision of \$13,131 and a deferred tax benefit of \$440.

The provision for income taxes for the three-months ended April 30, 2014 consists of a current tax provision of \$7,508 and a deferred tax provision of \$457.

The provision for income taxes for the six-months ended April 30, 2014 consists of a current tax provision of \$4,291 and a deferred tax provision of \$5,976.

## Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

On April 30, 2015, the Company had a current deferred tax asset of \$39,456 and a long-term deferred tax asset of \$4,438 included in other assets. On April 30, 2014, the Company had a current deferred tax asset of \$35,964 and a long-term deferred tax asset of \$2,291 included in other assets.

### [10] Subsequent events

On June 3, 2015 the Company, OPKO Health, Inc., a Delaware corporation ( OPKO ) and Bamboo Acquisition, Inc., a New Jersey corporation and a direct wholly owned subsidiary of OPKO ( Sub ), entered into an agreement and plan of merger (the Merger Agreement ). Pursuant to the Merger Agreement, Sub will be merged with and into the Company (the Merger ) and the Company will be the surviving corporation and OPKO s wholly owned subsidiary. The Merger is intended to qualify as a reorganization within the meaning of the Internal Revenue Code of 1986, as amended (the Code ).

At the effective time of the Merger (the Effective Time ), each issued and outstanding share of the Company s common stock, par value \$0.01 per share (the Company Common Stock ), (other than any shares of the Company Common Stock (including shares held in treasury by the Company) held by OPKO or any OPKO subsidiary or the Company or any Company subsidiary) will automatically be converted into and exchanged for the right to receive 2.75 shares (the Exchange Ratio ) of OPKO s common stock, par value \$0.01 per share (the OPKO Common Stock ). No fractional shares of OPKO Common Stock will be issued in the Merger, and the Company s shareholders will receive one share of OPKO Common Stock in lieu of any fractional shares, after taking into account all of the shares of the Company Common Stock represented by certificates or book-entries, delivered by such shareholder.

In addition, subject to certain limitations described in the Merger Agreement, each option to purchase shares of the Company Common Stock will be converted into and become rights with respect to the OPKO Common Stock and OPKO will assume each such option, in accordance with the terms of the applicable option plan and/or stock option agreement. The number of shares of OPKO Common Stock subject to such options will be equal to the number of shares of Company Common Stock subject to such options multiplied by 2.75, rounded down to the nearest whole share. The per share exercise price under each option will be adjusted by dividing the per share exercise price of such option by 2.75 and rounding up to the nearest cent.

Table of Contents

The obligations of the Company and OPKO to consummate the Merger are subject to customary conditions, including, but not limited to, obtaining the required approval of the Company's shareholders.

Subject to the satisfaction or waiver of the foregoing conditions and the other terms and conditions contained in the Merger Agreement, the transaction is expected to close in the second half of 2015.

The Merger Agreement contains certain termination rights for both the Company and OPKO in certain circumstances.

If the Merger Agreement is terminated under certain circumstances specified in the Merger Agreement, the Company will be required to pay OPKO a termination fee of up to \$54,000,000. In addition, under certain circumstances, the Company would be obligated to reimburse OPKO's out of pocket expenses incurred in connection with the Merger Agreement up to \$3,000,000.

**Forward-Looking Statements**

Statements included in this Annual Report on Form 10-Q (Quarterly Report) that are not historical in nature, are intended to be, and are hereby identified as forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as expects, anticipates, intends, plans, believes, seeks, estimates, will or words of similar meaning and include, but are not limited to, statements about the expected future business and financial performance of Bio-Reference Laboratories, Inc. and its subsidiaries. Such statements concern matters that involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods, performance or achievements, or industry results, to be materially different from any future results, performance or achievements described, implied or suggested herein. Although we believe our expectations are based upon reasonable assumptions, there can be no assurance that our financial goals will be realized.

Factors could cause actual results, performance or achievement to differ materially from those expressed or implied from these forward-looking statements include, but are not limited to, the factors discussed under Risk Factors as well as elsewhere herein, which may include:

Loss or suspension of a license or imposition of a fine or penalties under, or future changes in, the law or regulations of CLIA, or those of state laboratory licensing laws;

Failure to comply with HIPAA, which could negatively impact profitability and cash flows;

FDA regulation of Laboratory Developed Tests and clinical laboratories;

Failure to comply with federal and state anti-kickback laws;

Failure to maintain the security of patient-related information;

Failure to comply with the Federal Occupational Safety and Health Administration requirements and Needlestick Safety and Prevention Act;

## Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

Failure to comply with federal and state laws and regulations related to submission of claims for our services;

Changes in regulation and policies, including increasing downward pressure on health care reimbursement;

Changing relationships with payers, including the various state and multi-state Blues programs, suppliers and strategic partners; Efforts by third-party payors to reduce utilization and reimbursement for clinical testing services;

Failure to timely or accurately bill for our services;

Failure to integrate newly acquired businesses and the costs related to such integration;

Increased competition, including price competition;

Ability to attract and retain experienced and qualified personnel;

Failure to obtain and retain new clients and business partners, or a reduction in tests ordered or specimens submitted by existing clients;

Adverse litigation results; and

Failure to establish, and perform to, appropriate quality standards to assure that the highest level of quality is observed in the performance of our testing services.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this filing. We assume no obligation to update the forward-looking statements to reflect actual results or changes in the factors affecting such forward-looking statements.

### **Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

**[Dollars In Thousands Except Per Share Data, Total Patient Data Or Unless Otherwise Noted]**

#### **Overview**

We are a clinical diagnostic laboratory headquartered in northeastern New Jersey. We are a national laboratory in certain focused areas of laboratory testing and a full service laboratory in the larger metropolitan areas of New York, New Jersey, Maryland, Pennsylvania, Delaware, Washington DC, Florida, California, Texas, Illinois and Massachusetts.

We have developed a national reputation for our expertise in certain focused areas of clinical testing. GenPath Oncology, the name by which we are known for our cancer and oncology services, is recognized for the superior hematopathology services it provides throughout the country. Our Women's Health initiative, through which we provide dedicated services for obstetrics and gynecology practices, including a technically advanced multiplex process for identifying sexually transmitted infections, is offered as GenPath Women's Health. We are a full-service laboratory that primarily services physician office practices; our drivers pick up samples and deliver reports and supplies, we provide sophisticated technical support, phlebotomy services or patient service centers where appropriate, and electronic communication services in many cases. Physicians outside of our regional footprint send samples to our laboratory in order to take advantage of the expertise that we are able to provide in blood-based cancer pathology and associated diagnostics or to take advantage of the superior service,



Table of Contents

support and technologically advanced testing we offer in our Women's Health initiative. These accounts frequently send routine testing to us for processing along with specialized testing in order to simplify their diagnostic ordering and review procedures and to take advantage of our outstanding capability, service and support. Our correctional healthcare services are used throughout the country at prisons and jails. The focused markets we serve on a national basis outside of our regional footprint do not require many of the logistical and other ancillary support services required within the region. Even within our regional footprint, we provide the same services that we provide on a national basis as well as some regional focused diagnostic services, such as histology and pathology support services, substance abuse testing, fertility testing, hemostasis testing, women's health testing, and molecular diagnostics that are unavailable from many of the smaller regional competitors; testing in some of these areas may be provided outside of physician offices. Laboratorio Buena Salud is the first national testing laboratory dedicated to serving Spanish-speaking populations in the United States. All business is conducted in Spanish, including patient and physician interactions.

Over the last few years, there have been fundamental changes in the laboratory services industry. In the 1990s, the industry was negatively impacted by the growth of managed care, increased government regulation, and investigations into fraud and abuse. These factors led to revenue and profit declines and industry consolidations, especially among commercial laboratories. There are currently only three US publicly traded full service laboratories operating primarily in the U.S. While that means that the two national mega-laboratories and Bio-Reference Laboratories are the only remaining publicly traded full service commercial laboratories, there are numerous hospital outreach programs and smaller reference laboratories that compete for the commercial clinical laboratory business scattered throughout the country. Clinical laboratories have had to improve efficiency, leverage economies of scale, comply with government regulations and other laws and develop more profitable approaches to pricing. Moreover, there has been a proliferation of technology advancements in clinical diagnostics over the last decade that has created significant opportunities for new testing and growth.

As a full service clinical laboratory, we are constantly looking for new technologies and new methodologies that will help us to grow. Since the turn of the century, our size alone has made us attractive to companies that are driving the advances in technology. We represent a significant opportunity for these companies to market their products with a nationally recognized specialty provider in our focused areas of specialty or in one of the major population centers of the world—the New York Metropolitan area. We have had several successful strategic relationships with such technology opportunities. In addition to new technology opportunities, we have an extremely seasoned and talented management staff that has been able to identify emerging laboratory markets that are under-served or under-utilized. We have recently developed programs for cardiology, histology and women's health to go along with our existing hemostasis, hematopathology and correctional healthcare initiatives which have already been established and in which we have been increasing our market share for the past several years. We offer a comprehensive pre-natal program to leverage our presence in the women's health environment and we will continue to vigilantly seek focused diagnostic marketing opportunities where we can provide information, technology, service or support that expand and grow our clinical laboratory.

While we recognize that we are a clinical laboratory that processes samples, we also understand that we are an information company that needs to effectively communicate the results of our efforts back to healthcare providers. Laboratory results play a major role in the implementation of physician healthcare. Laboratory results are used to diagnose, monitor and classify health concerns. In many cases, laboratory results represent the confirming data in diagnosing complicated health issues. Since laboratory results play such an important role in routine physician care, we have developed informatics solutions that leverage our role in healthcare. We built a web-based solution to quickly, accurately, conveniently and competitively collect ordering information and deliver results. That solution is called CareEvolve. CareEvolve has been essential to our own operations. We license the technology to other laboratories throughout the country that they utilize to more effectively compete against the national laboratories. These other laboratories licensing our technology are typically not our competitors since they are outside our regional footprint.

We have also created our PSIMedica business unit that has developed a Clinical Knowledge Management (CKM) System that takes data from enrollment, claims, pharmacy, laboratory results and any other available electronic source to provide both administrative and clinical analysis of a population. The system uses proprietary algorithms to cleanse and configure the data and transfer the resulting information into a healthcare data repository. Using advanced cube technology methodologies, the data can be analyzed from a myriad of views and from highly granular transactional detail to global trended overview. Events such as the Hurricane Katrina in Louisiana and general pressures from the government

## Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

have made development of an electronic medical record system and Pay-for Performance reimbursement priority goals in the healthcare industry. A large portion of an individual's medical record consists of laboratory data and a key performance indicator in any Pay-for-Performance initiative is laboratory result data. Our CKM system is a mature, full functioning solution that will allow us to play a role in these important national initiatives.

To date, neither our PSIMedica business unit nor CareEvolve has produced significant revenues relative to the primary laboratory operations.



Table of Contents

**Second Quarter Fiscal 2015 Compared to Second Quarter Fiscal 2014**

NET REVENUES:

Net revenues for the three-month period ended April 30, 2015 were \$223,986 as compared to \$201,366 for the three-month period ended April 30, 2014. This represents an 11% increase in net revenues. This increase is due to an 8% increase in patient counts and an increase in revenue per patient of 3%. The number of patients serviced during the three-month period ended April 30, 2015 was 2,559, which was 8% greater when compared to the prior fiscal year's corresponding three-month period. This increase in patient counts is mainly due to the overall success of all our lines of business. Net revenue per patient for the three-month period ended April 30, 2015 was \$86.69 compared to net revenue per patient of \$84.18 for the three-month period ended April 30, 2014, an increase of 3%.

Our revenues and patient counts could be adversely affected by a number of factors, including, but not limited, to an extended economic downturn in general or healthcare economic conditions, an unexpected reduction in reimbursement rates, increased market penetration by our competitors or a substantial adverse change in federal regulatory requirements governing our industry.

COST OF SERVICES:

Cost of services increased from \$112,817 for the three-month period ended April 30, 2014 to \$125,003 for the three-month period ended April 30, 2015, an increase of 11%. This increase was related largely to our continuing integration expenses of our California operations.

GROSS PROFITS:

Gross profits increased to \$98,983 for the three-month period ended April 30, 2015 from \$88,549 for the three-month period ended April 30, 2014, an increase of 12%. This increase is in line with the increase in revenues.

GENERAL AND ADMINISTRATIVE EXPENSES:

General and administrative expenses for the three-month period ending April 30, 2014 were \$69,670 as compared to \$80,057 for the quarter ended April 30, 2015, an increase of 15%. This increase is slightly more than the increase in our net revenues and is mainly due to an increase in marketing expenses we incurred as the result of expanding our sales and marketing operations.

INTEREST EXPENSE:

Interest expense increased to \$666 during the three-month period ending April 30, 2015 from \$597 during the three-month period ended April 30, 2014. This increase is due to an increase in the utilization of our PNC Bank's credit line.

NET INCOME:

We realized net income of \$10,461 for the three-month period ended April 30, 2015, as compared to \$10,273 for the three-month period ended April 30, 2014, an increase of 2%. Pre-tax income for the period ended April 30, 2014 was \$18,238, compared to \$18,281 for the three-month period ended April 30, 2015, an increase of less than 1%. This small increase was primarily caused by an increase in our marketing expenses. The provision for income taxes decreased to \$7,820 for the three-month period ended April 30, 2015 from \$7,965 for the period ended April 30, 2014.

**Six Months 2015 Compared to Six Months 2014**

NET REVENUES:

Net revenues for the six-month period ended April 30, 2015 were \$432,820 as compared to \$382,635 for the six-month period ended April 30, 2014. This represents a 13% increase in net revenues. This increase is due to a 7% increase in patient counts while the revenue per patient increased by 6%. The number of patients serviced during the six-month period ended April 30, 2015 was 4,911, which was 7% greater when compared to the prior fiscal year's corresponding six-month period. This increase in patient counts is mainly due to the overall success of all our lines of business. Net revenue per patient for the six-month period ended April 30, 2014 was \$82.73 compared to net revenue per patient for the six-month period ended April 30, 2015 of \$87.36, an increase of 6%.

Our revenues and patient counts could be adversely affected by a number of factors, including, but not limited, to an extended economic downturn in general or healthcare economic conditions, an unexpected reduction in reimbursement rates, increased market penetration by our competitors or a substantial adverse change in federal regulatory requirements governing our industry as well as a failure to continue the sizeable annual percentage increase in base business.

Table of Contents

COST OF SERVICES:

Cost of services increased to \$244,082 for the six-month period ended April 30, 2015 from \$221,932 for the six-month period ended April 30, 2014. This represents a 10% increase in direct operating costs.

GROSS PROFITS:

Gross profits on net revenues increased to \$188,738 for the six-month period ended April 30, 2015 from \$160,703 for the six-month period ended April 30, 2014, an increase of 17%. Gross profit margins were 44% for the six-month period ended April 30, 2015 compared to 42% in the corresponding six-month period ended April 30, 2014.

GENERAL AND ADMINISTRATIVE EXPENSES:

General and administrative expenses for the six-month period ended April 30, 2015 were \$157,884 as compared to \$135,943 for the six-month period ended April 30, 2014. This represents an increase of 16%. This increase is 3% more than the increase in net revenues and is mainly due to additional marketing expenses incurred as we expanded our marketing operations.

INTEREST EXPENSE:

Interest expense increased to \$1,226 during the six-month period ending April 30, 2015 as compared to \$1,206 during the six-month period ending April 30, 2014, an increase of \$20. This increase is due to an increase in the utilization of our PNC Bank credit line.

INCOME:

We realized net income of \$17,094 for the six-month period ended April 30, 2015 as compared to \$13,227 for the six-month period ended April 30, 2014, an increase of 29%. Our operating income increased by 25% for the six-month period ended April 30, 2015 as compared to the six-month period ended April 30, 2014. Pre-tax income for the six-month period ended April 30, 2015 was \$29,785 as compared to \$23,494 for the period ended April 30, 2014, an increase of 27%. The provision for income taxes increased from \$10,267 for the period ended April 30, 2014, to \$12,691 for the current six-month period, an increase of 24%.

LIQUIDITY AND CAPITAL RESOURCES:

## Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

Our working capital at April 30, 2015 was \$217,644 as compared to \$207,285 at October 31, 2014, an increase of 5%. Our cash increased by \$7,639 during the current period. We increased our short-term debt by \$17 and repaid \$274 in existing debt. We had current liabilities of \$162,326 at April 30, 2015. We generated \$10,557 in cash from operations, compared to utilizing 188 for the six-month period ended April 30, 2014, an overall increase of \$10,745 in cash generated from operations year over year.

On May 14, 2015 a date subsequent to the period covered in these financial statements the Company further amended its PNC Bank Credit Line to increase the maximum that can be borrowed under the credit line to \$120,000 as well as extended the credit line through October 2020. This amendment is effective as of May 5, 2015. The other terms of the amendment remained substantially unchanged.

Accounts receivable, net of allowance for doubtful accounts, totaled \$285,361 at April 30, 2015, an increase of \$22,015 or 8% from October 31, 2014. Cash collected during the three-month period ended April 30, 2015 increased 11% over the comparable prior year three-month period.

Credit risk with respect to accounts receivable is generally diversified due to the large number of patients comprising our client base. We have significant receivable balances with government payors and various insurance carriers. Generally, we do not require collateral or other security to support customer receivables. However, we continually monitor and evaluate our client acceptance and collection procedures to minimize potential credit risks associated with our accounts receivable and establish an allowance for uncollectible accounts. As a consequence, we believe that our accounts receivable credit risk exposure beyond such allowance is not material to the financial statements.

A number of proposals for legislation continue to be under discussion that could substantially reduce Medicare and Medicaid reimbursements to clinical laboratories. Depending upon the nature of regulatory action, and the content of legislation, we could experience a significant decrease in revenues from Medicare and Medicaid, which could have a material adverse effect on us. We are unable to predict, however, the extent of which such actions will be taken if at all.

Billing for laboratory services is complicated and we must bill various payors, such as the individual, the insurance company, the government (federal or state), the private company or the health clinic. Other factors that may complicate billing include:

Table of Contents

Differences between fee schedules and actual reimbursement rates.

Incomplete or inaccurate billing information provided by physicians or clinics.

Disparity in coverage and information requirements.

Disputes with payors.

Internal and external compliance policies and procedures.

Significant costs are incurred as a result of our participation in government programs since billing and reimbursement for laboratory tests are subject to complex regulations. We perform the requested tests and report the results whether the billing information is correct or not or even missing. This adds to the complexity and slows the collection process and increases the aging of our accounts receivable ( A/R ). When patient invoices are not collected in a timely manner, the item is written off to the allowance. Days Sales Outstanding ( DSO ) for the period ended April 30, 2015 was 113 days, an increase of 10 days, or about 10%, from the 103 days that we reported for the period ended April 30, 2014. On a rolling basis, our actual collections represent between 98% and 102% of our net collectable revenues.

See Notes to our consolidated financial statements for the information on our short and long term debt.

We intend to expand our laboratory operations organically through marketing while also diversifying into related medical fields through acquisitions. These acquisitions may involve cash, notes, common stock and/or combinations thereof.

Tabular Disclosure of Contractual Obligations

	Next Four Years and Thereafter (\$)	FY 2015 (\$)
Long-Term Debt	3,145	524
Capital Leases	12,789	6,624
Operating Leases	4,637	8,909
Purchase Obligations	128,626	73,709
Long-Term Liabilities under Employment and Consultant Contracts	9,113	4,582

Our cash balance at April 30, 2015 totaled \$25,146 as compared to \$17,507 at October 31, 2014. We believe that our cash position, the anticipated cash generated from future operations and the availability of our credit line with PNC Bank will meet our anticipated cash needs for the next 12 months.

Impact of Inflation

To date, inflation has not had a material effect on our operations.

#### Critical Accounting Policies

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported periods.

#### Accounting for Intangible and Other Long-Lived Assets

We evaluate the possible impairment of our long-lived assets, including intangible assets. We review the recoverability of our long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. Evaluation of possible impairment is based on our ability to recover the asset from the expected future pretax cash flows (undiscounted and without interest charges) of the related operations. If the expected undiscounted pretax cash flows are less than the carrying amount of such asset, an impairment loss is recognized for the difference between the estimated fair value and the carrying amount of the asset.

#### Accounting for Revenue

Service revenues are principally generated from laboratory testing services including chemical diagnostic tests such as blood analysis, urine analysis and genetic testing among others. Service revenues are recognized at the time the testing services are performed and are reported at their estimated net realizable amounts.

Service revenues before provision for bad debts are determined utilizing gross service revenues net of contractual adjustments and discounts. Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or a commercial

Table of Contents

insurance provider to pay all or a portion of their healthcare expenses; the majority of services provided by BRLI are to patients covered under a third party payor contract. In certain cases, the individual has no insurance or does not provide insurance information and in other cases tests are performed under contract to a professional organization (such as physicians, hospitals, and clinics) which reimburse BRLI directly; in the remainder of the cases, BRLI is provided the third party billing information and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI. Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and providing coverage (reimbursement) for specific tests. Estimated revenues are established based on a series of highly complex procedures and judgments that require industry specific healthcare experience and an understanding of payor methods and trends. We review our calculations on a monthly basis in order to make certain that we are properly allowing for the uncollectable portion of our gross billings due to the contractual adjustments and discounts and that our estimates remain sensitive to variances and changes within our payor groups. The contractual allowance calculation is made on the basis of historical allowance rates for the various specific payor groups on a monthly basis with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions and shifts in the testing being performed. This calculation is routinely analyzed by BRLI on the basis of actual allowances issued by payors and the actual payments made to determine what adjustments, if any, are needed. The table below shows the adjustments made to gross service revenues to arrive at net revenues, the amount reported on our statement of operations.

	(\$)			
	Three Months Ended April 30, [Unaudited]		Six Months Ended April 30, [Unaudited]	
	2015	2014	2015	2014
Gross Service Revenues	1,175,282	1,017,621	2,240,575	1,927,499
<b>Contractual Adjustments and Discounts:</b>				
Medicare/Medicaid Portion	101,262	94,520	195,325	183,439
All Other Third Party Payors*	838,004	706,234	1,587,205	1,330,379
Total Contractual Adjustments and Discounts	939,266	800,754	1,782,530	1,513,818
Service Revenues Net of Contractual Adjustments and Discounts	236,016	216,867	458,045	413,681
Patient Service Revenue Provision for Bad Debts**	12,030	15,501	25,225	31,046
Net Revenues	223,986	201,366	432,820	382,635

\* All Other Third Party and Direct Payors consists of almost eight hundred distinct payors, including commercial health insurers and administrators as well as professionally billed accounts such as physicians, hospitals, clinics and other direct billed accounts.

\*\* Represents the amount of Bad Debt Expense that is required to be presented as a deduction from patient service revenue (net of contractual allowances and discounts) pursuant to ASU No. 2011-7.

When new business is received by BRLI, service revenues net of contractual adjustments and discounts are calculated by reducing gross service revenues by the estimated contractual allowance. The Patient Service Revenue Provision for Bad Debts represents the amount of bad debt expense expected to occur on patient service revenue based upon our experience. The remaining bad debt expense is presented as part of operating expenses. The bad debt expense presented as part of operating expense represents the bad debt expense related to receivables from service revenues determined after taking into account our ability to collect on such revenue.

## Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

BRLI recognized the amounts in subsequent periods for actual allowances/discounts to gross service revenue; bad debt may have been adjusted over the same periods of time to maintain an accurate balance between net revenues and actual revenues. Management has reviewed the allowances/discounts recognized in subsequent periods and believes the amounts to be immaterial. A number of proposals for legislation or regulation continue to be under discussion which could have the effect of substantially reducing Medicare reimbursements for clinical laboratories or introducing cost sharing to beneficiaries. One such legislation is Protecting Access to Medicare Act of 2014 (Public Law 113 93)( PAMA ) was signed into law on April 1, 2014. The legislation directed CMS to conduct a market survey and to determine whether Medicare is reimbursing at a commercially reasonable rates. To date, CMS has fallen behind the schedule legislated in PAMA. As the result, the current reimbursement rates remain unchanged, subject to typical annual reviews, until 2017.



Table of Contents

It is typically the responsibility of the patient to pay for laboratory service bills. Most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or commercial insurance to pay all or a portion of their healthcare expenses; this represents the major portion of payment for all services provided by BRLI. In certain cases, the individual has no insurance or does not provide insurance information; in the remainder of the cases, BRLI is provided the third party billing information, usually by the referring physician, and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI. Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and coverage of specific tests. BRLI routinely reviews the reimbursement policies and subsequent payments and collection rates from these different types of payors. Contractual adjustments and discounts are recorded as reductions to gross service revenues and are collectively referred to as the contractual allowance. BRLI has not been required to record an adjustment in a subsequent period related to revenue recorded in a prior period which was material in nature. Aging of accounts receivable is monitored by billing personnel and follow-up activities including collection efforts are conducted as necessary. BRLI writes off receivables against the allowance for doubtful accounts when they are deemed uncollectible. For client billing, accounts are written off when all reasonable collection efforts prove to be unsuccessful. Patient accounts, where the patient is directly responsible for all or a remainder portion of the account after partial payment or denial by a third party payor, are written off after the normal dunning cycle has occurred, although these may be subsequently transferred to a third party collection agency after being written off. Third party payor accounts are written off when they exceed the payer's timely filing limits. Accounts Receivable on the balance sheet is net of the following amounts for contractual credits and doubtful accounts:

	[Unaudited] April 30, 2015	(\$) October 31, 2014
Contractual Credits/Discounts	582,180	513,466
Doubtful Accounts	81,505	83,276
Total Allowance	663,685	596,742

**OPKO Merger Agreement**

On June 3, 2015 the Company, OPKO Health, Inc., a Delaware corporation ( "OPKO" ) and Bamboo Acquisition, Inc., a New Jersey corporation and a direct wholly owned subsidiary of OPKO ( "Sub" ), entered into an agreement and plan of merger (the "Merger Agreement" ). Pursuant to the Merger Agreement, Sub will be merged with and into the Company (the "Merger" ) and the Company, as the surviving corporation, will become OPKO's wholly owned subsidiary. At the effective time of the Merger, each issued and outstanding share of the Company's common stock will automatically be converted into and exchanged for the right to receive 2.75 shares of OPKO's common stock. For further information about the Merger, see Note 10, "Subsequent Events" of the Notes to Consolidated Financial Statements in Part I herein.

**Item 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK [Not in Thousands]**

We do not invest in or trade instruments that are sensitive to market risk. We also do not have any material foreign operations or foreign sales so we have no exposure to foreign currency exchange rate risk.

We do have exposure to both rising and falling interest rates. At April 30, 2015, advances of approximately \$49,315,000 under our PNC Bank Credit Line were subject to interest charges at the bank's then prime rate of 3.50%.

We estimate that our monthly cash interest expense at April 30, 2015 was approximately \$204,000 and that a one percentage point increase or decrease in short-term rates would increase or decrease our monthly interest expense by approximately \$29,000.

**Item 4 CONTROLS AND PROCEDURES**

An evaluation was performed under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, as to the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on that evaluation, our principal executive officer and our principal financial officer have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC forms and rules, and include controls and procedures designed to ensure that information required to be disclosed by us in such reports is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate to allow timely decisions regarding required disclosures.

There have been no changes in our internal control over financial reporting during the fiscal quarter ended April 30, 2015 that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

Table of Contents

**BIO-REFERENCE LABORATORIES, INC.**

**PART II OTHER INFORMATION**

**Item 1 Legal Proceedings**

*Bio-Reference Laboratories, Inc. v. Horizon Healthcare Services, Inc. d/b/a Horizon Blue Cross Blue Shield of New Jersey*

On December 18, 2013, the Company filed an action in the Superior Court of New Jersey against Horizon Blue Cross Blue Shield of New Jersey ( Horizon ), captioned *Bio-Reference Laboratories, Inc. v. Horizon Healthcare Services, Inc. d/b/a Horizon Blue Cross Blue Shield of New Jersey*, Docket No. BER L-009748-13 (N.J. Super. Ct. Bergen Cnty.). The Company has been an in-network provider to Horizon s preferred provider organization ( PPO ) members for more than 20 years and filed the lawsuit after attempts to resolve its dispute with Horizon were unsuccessful.

The Company currently provides services to Horizon pursuant to an Ancillary Services Provider Agreement entered into in 2003 and amended in 2007. The central claims in the lawsuit arise from the Company s performance of laboratory services since at least 2008 for members of Horizon s NJ DIRECT plan, who receive benefits under a program that Horizon has bid, promoted, and represented to be a PPO product for New Jersey state, county, and municipal workers and teachers. The lawsuit alleges that, despite these representations, Horizon has been improperly treating NJ DIRECT as a Managed Care program in its dealings with the Company, thereby costing the Company more than \$20,000,000 in unreimbursed services and depriving state beneficiaries of valuable rights and benefits to which they are entitled. The lawsuit alleges that Horizon furthered its fraud against the Company by means of a sham Request for Proposal issued in 2011 and through false and incorrect communications to the Company and other providers. The Company asserts claims for breach of contract, breach of the implied covenant of good faith and fair dealing, and fraud against Horizon. In addition to compensatory damages, the Company seeks to recover punitive damages from Horizon due to Horizon s intentional and malicious misconduct. The Company also seeks declaratory and injunctive relief.

On February 5, 2014, Horizon filed a motion to dismiss the complaint, which the Company opposed. On March 28, 2014, the Honorable Robert C. Wilson of the Superior Court of New Jersey issued an oral ruling denying Horizon s motion to dismiss without prejudice pending the completion of discovery. The Company and Horizon are conducting discovery, which is currently scheduled to close on July 30, 2015. The Company intends to vigorously prosecute its claims against Horizon.

**Item 5 OTHER INFORMATION**

On June 3, 2015, the Company entered into a new employment agreement (the CEO Contract ) with its Chief Executive Officer, Dr. Marc D. Grodman, and OPKO, effective as of, and contingent upon, the closing of the transactions contemplated by the Merger Agreement. The disclosure regarding, and the copy of, the CEO Contract that was filed by the Company on Form 8-K with the Securities and Exchange Commission on June 4, 2015 (the June 4 Form 8-K ) contained a typographical error with respect to Dr. Grodman s base salary. Dr. Grodman s current annual base salary is \$1,175,676. A corrected version of the CEO Contract is filed hereto as Exhibit 10.3 to this Form 10-Q, which is incorporated herein by reference and replaces Exhibit 10.1 filed with the June 4 Form 8-K.

**Item 6 EXHIBITS**

- 10.1 Fourteenth Amendment to Loan Documents
- 10.2 Thirteenth Amended and Restated Secured Revolving Note
- 10.3 Employment Agreement dated as of June 3, 2015 among Bio-Reference Laboratories, Inc., OPKO Health, Inc. and Marc D. Grodman
- 31.1 Certification of Chief Executive Officer
- 31.2 Certification of Chief Financial Officer
- 32.1 Certification Pursuant to 18 U.S.C. Section 1350 of Chief Executive Officer
- 32.2 Certification Pursuant to 18 U.S.C. Section 1350 of Chief Financial Officer
- 101 Interactive Data File

Table of Contents

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BIO-REFERENCE LABORATORIES, INC.  
(Registrant)

/S/ Marc D. Grodman M.D.  
Marc D. Grodman, M.D.  
President and Chief Executive Officer

/S/ Nicholas Papazicos  
Nicholas Papazicos  
Senior Vice President, Chief Financial and Chief Accounting Officer

Date: June 8, 2015